7 Best Peptides for Bulking (Muscle Gain Phase)

What to Know Before Choosing a Peptide for Bulking

If you are searching for peptides to support a muscle gain phase, the honest starting point is understanding what this category of compound actually does. Most peptides discussed for bulking work by nudging the body to release more growth hormone, which the liver then converts into IGF-1, the downstream signal that drives muscle protein synthesis. A smaller group bypass that axis entirely and act directly on muscle tissue. Neither category is a replacement for anabolic steroids in terms of raw mass potential, and neither replaces a caloric surplus and consistent training. What they offer is a real but modest supporting role, and the field is worth understanding clearly before making any decision.

Every compound in this guide earned its place by one criterion: people use it for bulking, or are actively discussing using it for that purpose. That standard is deliberately broad. FDA-approved, telemedicine-prescribed, and research-only compounds are all included. A compound with only community-reported use belongs on this list just as much as one with clinical trial data behind it, because leaving it off would mean withholding information about something people are genuinely reaching for. Where evidence is thin, this guide says so plainly. Where it is solid, it says that too.

The entries are numbered to give the list a spine, and the title reflects that count. The numbering reflects how prominently each compound appears in research and real-world use for this goal, not a recommendation of one compound over another. The compound that ranks first in prominence of use is not necessarily the right one for you. That depends on your specific situation, and it is exactly what a personalized plan is designed to work out.

1. CJC-1295 with Ipamorelin: The Foundation GH-Axis Stack

CJC-1295 and Ipamorelin are almost always discussed together for bulking, because they are almost always used together. Understanding each compound individually makes the combination clearer.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone, the signal your hypothalamus sends to the pituitary to trigger a GH pulse. It binds to GHRH receptors on the pituitary and extends the duration and amplitude of those pulses. The version without DAC, which stands for drug affinity complex and dramatically extends half-life, is the form most commonly associated with performance use because it works in a pattern closer to the body's natural pulsatile rhythm rather than creating a continuous flat elevation of GH.

Ipamorelin is a selective GHRP, or growth hormone-releasing peptide. It works through a different receptor than CJC-1295, specifically the ghrelin receptor known as GHS-R1a, which means the two compounds activate GH release through complementary pathways simultaneously. When used together, the resulting GH response is substantially larger than either compound produces alone. Ipamorelin's key differentiator among GHRPs is selectivity: it triggers GH release without meaningfully raising cortisol or prolactin, the stress and reproductive hormones that older GHRPs tend to elevate. That cleaner profile makes it the most commonly recommended starting point for people new to GH secretagogues.

The GH released through this combination travels to the liver, which responds by producing IGF-1. IGF-1 then acts on muscle cells to activate the PI3K/Akt/mTOR pathway, which is the primary molecular driver of muscle protein synthesis, essentially the cellular on-switch for building new tissue.

On the clinical evidence front, a 2023 systematic review of five randomized controlled trials examined the CJC-1295 and ipamorelin combination and found lean mass gains in the range of roughly 1.2 to 2.1 kilograms over 8 to 16 weeks in older adults. That figure is real but modest, and it was not superior to resistance training alone in healthy, trained adults. No published peer-reviewed study has tested this specific combination in humans for muscle gain as its primary outcome. What makes this stack dominant in the conversation is not a deep evidence base but a combination of plausible mechanism, relatively clean safety profile compared to other options in the category, and consistent presence across community protocols.

On the regulatory side, CJC-1295 was placed on an FDA ban list in 2024 citing cardiac risk concerns, which changed its availability through compounding pharmacies. Ipamorelin was temporarily banned in 2023 but was removed from that list in September 2024 and currently sits in a different regulatory position. Both are banned by WADA for competitive athletes.

2. GHRP-6: For the Appetite-Driven Caloric Surplus

GHRP-6 is the one peptide in the bulking conversation that people choose specifically because of a side effect. It triggers genuine, intense hunger, and for anyone who struggles to eat enough calories to support a mass-building phase, that is not a side effect to manage. It is the whole point.

The mechanism works through two channels at once. Like Ipamorelin, GHRP-6 activates the ghrelin receptor GHS-R1a on pituitary cells, driving GH release. Unlike Ipamorelin, GHRP-6 also activates ghrelin signaling in the hypothalamus, specifically the NPY and AgRP pathways in the arcuate nucleus, which are the brain's primary appetite-stimulating circuits. The hunger that follows is not a subtle increase. Users across community protocols consistently describe it as an urgent, near-irresistible drive to eat, typically arriving 45 to 90 minutes after dosing. For a hard gainer trying to hit a significant daily caloric surplus, this effect is the primary reason GHRP-6 appears on bulking lists rather than general GH optimization lists.

The GH release from GHRP-6 is also among the most potent of any GHRP class compound. When stacked with CJC-1295, community reports consistently describe GH responses that are substantially larger than either compound produces alone, which is why the CJC-1295 plus GHRP-6 combination is often called the classic bulking stack.

The trade-off is a less selective side-effect profile than Ipamorelin. GHRP-6 can elevate cortisol and prolactin at higher amounts, water retention is commonly reported, and headaches and nausea have been noted, particularly at higher amounts. The prolactin and cortisol elevation makes it a less appealing option for people prioritizing body composition quality over total caloric throughput.

No human clinical trial data exists specifically examining GHRP-6 for muscle gain in healthy adults as of 2026. Its place in the bulking conversation rests on its mechanism, its GH-releasing potency, and its consistent role in community protocols as the appetite tool in a GH secretagogue stack. GHRP-6 is classified as a research chemical, is not FDA-approved for human use, and is banned by WADA.

3. IGF-1 LR3: For Direct Muscle Cell Activation

IGF-1 LR3 is the compound that most clearly separates itself mechanistically from the rest of this list. Every other entry works upstream, persuading the pituitary or hypothalamus to produce more GH, which the liver then converts into IGF-1. IGF-1 LR3 skips the entire upstream axis and delivers the anabolic signal directly to muscle cells.

IGF-1 LR3 is a modified version of insulin-like growth factor 1. The modifications, an amino acid change at position 3 and a short extension at the N-terminus, prevent it from binding to IGF-binding proteins in circulation. Those binding proteins are what normally mop up free IGF-1 quickly, limiting its active window. Without that interference, IGF-1 LR3 has a substantially extended half-life compared to standard IGF-1, meaning more time for the compound to find and activate receptors on muscle cells.

Once bound to IGF-1 receptors on muscle tissue, it activates the same PI3K/Akt/mTOR protein synthesis pathway as the IGF-1 produced downstream from GH secretagogues. The theoretically meaningful distinction is satellite cell activation. Satellite cells are the specialized stem cells that generate new muscle fibers rather than simply enlarging existing ones. Activation of satellite cells drives what researchers call hyperplasia, which is the creation of new fibers rather than the enlargement of current ones, and this is considered distinct from the hypertrophy that most training and most other peptides support. Users who report pronounced pump effects from IGF-1 LR3 tend to attribute this to both acute cellular swelling from enhanced nutrient uptake and this deeper tissue-level activity.

The risk profile is the most significant in this category. Hypoglycemia is a real and potentially serious concern, because the compound's activity on cellular glucose transport means blood sugar can drop sharply without adequate carbohydrate and protein intake around dosing. There are also theoretical long-term concerns about sustained IGF-1 receptor activation and uncontrolled cell growth, concerns grounded in the well-established role of IGF-1 signaling in cancer biology.

No controlled human trial data exists for IGF-1 LR3 as a muscle-building agent in healthy adults. Mecasermin, the FDA-approved IGF-1 based therapy known as Increlex, exists but is approved only for severe primary IGF-1 deficiency in children and is not relevant to performance use. IGF-1 LR3 is sold as a research chemical, is not FDA-approved for this or any performance-related indication, and is banned by WADA. Its place in this list reflects genuine and substantial community use, particularly among more advanced users, with an evidence base that is entirely preclinical and experiential rather than clinical.

4. MK-677: The Oral GH Secretagogue

MK-677, also known as Ibutamoren, occupies an unusual position in this category. It is not technically a peptide but a small non-peptide molecule. It is consistently grouped with peptides in the bulking conversation, however, because it appears on virtually every list of compounds people use for muscle gain and works through the same ghrelin receptor pathway as the GHRP class. The reason it belongs here is straightforward: a significant number of people who want the effects of a GH secretagogue choose MK-677 specifically because it is taken orally rather than injected.

MK-677 activates GHS-R1a, the ghrelin receptor, triggering pituitary GH release and downstream IGF-1 elevation. Its GH-raising and IGF-1-raising effects are well-confirmed in human studies. It also stimulates appetite through ghrelin pathway activation, similar to GHRP-6 but generally described as less intense. And it consistently improves deep sleep quality, which matters for muscle gain because the largest natural GH pulses of the day occur during slow-wave sleep.

The community reception for MK-677 specifically as a bulking compound is more divided than its popularity would suggest. Across Reddit communities and peptide forums, a recurring criticism is that a meaningful portion of weight gained while using it is water and fat rather than lean tissue, particularly at higher amounts. The combination of appetite stimulation and water retention can read as progress on the scale while body composition changes remain modest. Users who report the most positive experiences tend to be those who managed caloric quality carefully rather than simply eating to appetite.

No robust human RCT data demonstrates meaningful lean mass gains in healthy, trained adults from MK-677 for muscle building. Human studies confirm the GH and IGF-1 elevation reliably. The lean mass translation in trained, healthy people remains unestablished at the clinical level. MK-677 is sold as a research chemical in the United States, is not FDA-approved for human use, and is banned by WADA. Long-term safety data is absent, and the combination of sustained IGF-1 elevation and effects on insulin sensitivity are concerns that appear repeatedly in safety-focused discussions.

5. Follistatin 344: The Myostatin Inhibition Approach

Follistatin 344 represents a fundamentally different theory of muscle growth than the GH-axis peptides that dominate this list. Rather than pushing growth signals harder, it works by removing a brake.

Myostatin is a protein in the TGF-beta family that the body uses to regulate how much muscle can grow. It acts as a natural ceiling on hypertrophy, a built-in governor. Follistatin 344 binds to and neutralizes myostatin along with several related TGF-beta family proteins including activin, and in animal models this suppression produces dramatic results. Myostatin-knockout mice and cattle carry substantially more muscle mass than their normal counterparts, and the mechanism translates clearly in those experimental systems.

The appeal for advanced users is straightforward in theory: if gains have stalled because you have hit the ceiling your myostatin levels allow, removing that brake should unlock further growth. This is the framing used in bodybuilding communities that discuss Follistatin 344. In practice, the gap between that animal-model rationale and confirmed human outcomes is the defining feature of this compound's evidence picture.

No controlled human clinical data exists for Follistatin 344 as a hypertrophy agent. A 2026 review in the American Journal of Sports Medicine stated that significant research regarding safety and efficacy is required before definitive recommendations can be made for this class of compounds. Community discussion about Follistatin 344 is thinner than discussion about GH secretagogues, with most commentary acknowledging the theoretical appeal rather than reporting substantial personal results. The mechanism is compelling in animal data. The human evidence is absent.

Follistatin 344 is sold as a research chemical with no FDA-approved indication relevant to healthy adults seeking muscle gain and no prescription pathway. It is banned by WADA. The long-term safety profile is unknown, and the compound's broad activity on TGF-beta family signaling raises open questions about effects on other tissue types including cardiac muscle and reproductive function.

6. Sermorelin: The Medically Supervised Option

Sermorelin is the first 29 amino acids of endogenous growth hormone-releasing hormone, making it the closest thing to the body's own GHRH signal that the GH-secretagogue category offers. It holds an FDA approval for diagnostic testing of GH secretion and has a longer track record in clinical use than any other GHRH analog discussed in the performance space.

The mechanism is the same as CJC-1295: binding to GHRH receptors on pituitary cells to amplify GH release and downstream IGF-1 production. Where Sermorelin differs from CJC-1295 is in potency and context of use rather than in mechanism. It produces a more modest GH response than synthetic GHRH analogs with their engineered half-life extensions, and it is most often used by people whose primary goal is GH optimization under medical supervision rather than maximum performance output.

In the bulking conversation specifically, Sermorelin tends to be the recommendation for people who want GH axis support but prioritize safety, prefer to work within a telehealth framework, or are less experienced with injectable peptide protocols. Anti-aging and functional medicine clinics have been prescribing it off-label for GH optimization for years, which means there is more clinical familiarity with its use and its side-effect profile than most compounds in this category carry.

The evidence base for Sermorelin as a muscle-building agent in healthy, trained adults is limited in the same ways as the rest of this category. Its GH-releasing effect is established. The lean mass translation for performance-focused use rests on that mechanism and on clinical familiarity rather than on dedicated trials in trained populations. What genuinely distinguishes it is the prescribability: Sermorelin can be obtained through a physician, giving it a different access pathway and a different level of medical oversight compared to research chemicals obtained without a prescription.

7. BPC-157: For Training Consistency Through Recovery

BPC-157 sits apart from every other compound on this list because it does not contribute to muscle growth directly. It belongs here because of what it enables: the ability to train consistently and at high volume through the minor and moderate injuries that accumulate during an aggressive bulking phase.

A serious muscle gain phase involves heavy, frequent resistance training. That load reliably produces soft tissue stress, joint inflammation, and the nagging connective tissue issues that force people to reduce training intensity or take extended breaks. BPC-157, a pentadecapeptide derived from a protective protein found in gastric secretions, is one of the most-discussed compounds for accelerating recovery from exactly this kind of damage. Its proposed mechanism centers on promoting the growth of new blood vessels, a process called angiogenesis, into damaged tissue, which speeds delivery of the materials needed for repair. It also appears to modulate inflammatory signaling and may influence healing of tendons, ligaments, and muscle through these pathways.

The honest picture on human evidence is direct: as of 2026, no randomized controlled trial in humans has been published for BPC-157 for any indication. The sole human-use data comes from a 12-patient retrospective case series on chronic knee pain with no control group and no blinding. The preclinical animal literature is extensive and generally shows accelerated tissue repair across multiple injury models, but the translation to confirmed human outcomes has not been established in controlled research.

Despite that evidence gap, BPC-157 is one of the most consistently mentioned compounds across peptide communities, with a substantial volume of user-reported experiences describing reduced recovery time, relief from nagging joint and tendon issues, and the ability to maintain training frequency through periods where the alternative would be rest or reduced intensity. Its place on this list reflects that breadth of real-world use and the indirect but genuine relevance to a successful bulking phase. BPC-157 is sold as a research chemical, is not FDA-approved for any indication, and is banned by WADA.

How These Peptides Compare

Frequently Asked Questions

Are these bulking peptides legal to buy in the United States?

The legal status varies by compound and matters practically. Sermorelin can be prescribed by a physician and obtained through a licensed pharmacy. MK-677, CJC-1295, Ipamorelin, GHRP-6, IGF-1 LR3, Follistatin 344, and BPC-157 are all sold as research chemicals in the United States, meaning they are not approved for human use and are not legally available for personal consumption, though they are widely accessible. CJC-1295 was specifically targeted by the FDA in 2024 citing cardiac concerns, which further changed its availability through compounding channels. Athletes subject to WADA testing should know that every compound on this list is banned in competition.

How much muscle can someone realistically expect from GH-axis peptides?

The honest answer from available clinical data is modest gains. A 2023 systematic review found the CJC-1295 and Ipamorelin combination produced roughly 1.2 to 2.1 kilograms of lean mass over 8 to 16 weeks in older adults, which is the most concrete human figure available for this category. In healthy, trained adults, that gain was not reliably superior to resistance training alone. Peptides in this category function as supportive tools that work alongside training and nutrition, not as replacements for either. Community reports more often describe improved recovery, better sleep quality, and a more solid muscle texture rather than dramatic size changes.

Do you need a prescription for any of these peptides?

Sermorelin requires a prescription and is available through licensed physicians and telemedicine clinics that specialize in GH optimization. Every other compound discussed in this guide, including Ipamorelin, GHRP-6, IGF-1 LR3, MK-677, BPC-157, and Follistatin 344, is sold as a research chemical without a prescription but is not approved for human consumption. Working with a knowledgeable clinician regardless of which compound you explore is worth considering given the metabolic effects involved.

How long do bulking peptide protocols typically run?

Based on community protocols and the clinical study windows in available literature, most GH secretagogue protocols for bulking run 8 to 16 weeks. Shorter cycles tend to appear with more potent or higher-risk compounds like IGF-1 LR3, where receptor downregulation and risk concerns favor a shorter window. Sermorelin under medical supervision is sometimes used for longer periods given its established clinical profile. Most protocols include an off period after the on phase, typically several weeks, to allow receptor sensitivity to reset. These are general patterns from community use, not clinical recommendations.

What is the difference between GH secretagogues and IGF-1 LR3 for bulking?

GH secretagogues like CJC-1295, Ipamorelin, GHRP-6, and Sermorelin work upstream: they signal the pituitary to release more GH, which the liver converts to IGF-1, which then acts on muscle cells. IGF-1 LR3 works downstream: it bypasses the pituitary and liver entirely and delivers the IGF-1 signal directly to muscle tissue. The practical differences include onset and duration of action, the risk profile (IGF-1 LR3 carries a more significant hypoglycemia risk than the upstream options), and the theoretical capacity for satellite cell activation and new fiber generation that direct IGF-1 receptor activation may provide. Most people begin with upstream options before considering downstream compounds.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for bulking and muscle gain in one place.